Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Initiation of treatment of diabetes Clear all
Completed Phase 4 Interventional

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

NCT05922033
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 3, 2026, 4:53 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Testing an Integrated Care Model Trial

NCT06448429
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Usual care, Collaborative care model (CoCM)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 99 Years
Enrollment
9,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

NCT00418522
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Inhaled Insulin (Exubera)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 3, 2026, 4:53 PM EDT
Not listed No phase listed Observational

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

NCT05751525
View directory record Official record
Conditions
Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy
Interventions
Sulfonylurea
Drug
Lead sponsor
Royal Devon and Exeter NHS Foundation Trust
Other
Eligibility
2 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 3, 2026, 4:53 PM EDT
Recruiting Not applicable Interventional

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

NCT05734313
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes
Interventions
Unified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM)
Behavioral · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Not applicable Interventional

Implementing Continuous Glucose Monitoring in Primary Care for Patients With Diabetes

NCT05336214
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Continuous Glucose Monitoring
Interventions
Virtual CGM initiation service, Online educational module on CGM, Practice facilitation
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Insulin Management System
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 8 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Metformin, healthy lifestyle intervention (LIFE)
Drug · Behavioral
Lead sponsor
Melissa Delbello
Other
Eligibility
8 Years to 19 Years
Enrollment
1,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
29
States / cities
Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of the Nutrition-Supported Diabetes Education Program

NCT05067452
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Food support, Case-management
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Integration of Hypertension Management Into HIV Care in Nigeria

NCT04704336
View directory record Official record
Conditions
Human Immunodeficiency Virus, Hypertension
Interventions
Task-shifting strategy for HTN control (TASSH) protocol
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Hybrid Closed Loop Insulin Delivery System in Hypoglycemia

NCT03215914
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia Unawareness, Nocturnal Hypoglycemia, Hypoglycemia Night, Hypoglycemia
Interventions
MiniMed 670G system
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 3, 2026, 4:53 PM EDT
Not yet recruiting Phase 4 Interventional

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

NCT06682351
View directory record Official record
Conditions
Prediabetes / Type 2 Diabetes
Interventions
Metformin, GLP-1A, MED
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

NCT06046560
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes
Interventions
SGLT2 inhibitor, GLP-1 RA, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
27 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 3, 2026, 4:53 PM EDT
Completed No phase listed Observational

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

NCT07417618
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, ASCVD
Interventions
Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60,000 participants
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 4 Interventional

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

NCT00101751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, dietary regimen
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Peer Support to Aid in Prevention and Treatment in Prediabetes

NCT03689530
View directory record Official record
Conditions
PreDiabetes
Interventions
Peer Support, Enhanced Usual Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Oakland, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 3, 2026, 4:53 PM EDT
Withdrawn No phase listed Observational

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

NCT05102071
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
empagliflozin, metformin, sulfonylurea
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 3, 2026, 4:53 PM EDT
Not listed Phase 2Phase 3 Interventional

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes

NCT04011020
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Hackensack, New Jersey • Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 3, 2026, 4:53 PM EDT
Not listed Phase 4 Interventional

Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices

NCT02361489
View directory record Official record
Conditions
Diabetes Type II
Interventions
V-Go
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 3, 2026, 4:53 PM EDT
Active, not recruiting Not applicable Interventional

Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

NCT05000021
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring, Continuous Glucose Monitoring (CGM)
Behavioral · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 3, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 3, 2026, 4:53 PM EDT